Professor Anthony Maraveyas graduated from Athens Medical School in 1983 and completed his medical training in internal medicine in 1990. During this time he developed an interest in the field of medical oncology. Commenced studies at the ICRF laboratories, RPMS Hammersmith, leading PhD on the application of radiolabeled monoclonal antibodies in the treatment of head and neck Cancer.
He subsequently became a lecturer at St George’s Hospital Medical School studying the application of allogeneic vaccines in Melanoma. He became Senior Lecturer in Medical Oncology the University of Hull helping establish the Cancer services for HEYCCN (Humber and East Yorkshire Coast Cancer Network) and the new medical School of HYMS (Hull York Medical School). He was promoted to Reader in HYMS in 2011.
He treats gastrointestinal cancers studying the impact of thrombosis on these patients, and the impact of incidental pulmonary embolism in cancer patients. He also treats melanoma and renal cell carcinoma.
His basic research interests include the targeting of cancer neo-vasculature and the haemostatic apparatus (Tissue Factor) to interfere with cancer metastasis. CI for the FRAGEM trial that was the first to demonstrate the thromboprophylaxis potential of dalteparin in ambulant patients with pancreatic cancer. NCRN director for HEYCCRN and a co-director of TRAD Alliance with Prof. Miriam Johnson and Dr. Simon Noble.